Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SLS Stock Forecast 2025-2026
$1.74
Current Price
$256.55M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SLS Price Targets
+331.0%
To High Target of $7.50
+302.3%
To Median Target of $7.00
+244.8%
To Low Target of $6.00
SLS Price Momentum
+7.4%
1 Week Change
+9.4%
1 Month Change
+52.6%
1 Year Change
+67.3%
Year-to-Date Change
-29.8%
From 52W High of $2.48
+126.0%
From 52W Low of $0.77
📊 TOP ANALYST CALLS
Did SLS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if SELLAS is one of their latest high-conviction picks.
Latest SLS Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, SLS has a bullish consensus with a median price target of $7.00 (ranging from $6.00 to $7.50). The overall analyst rating is N/A (N/A/10). Currently trading at $1.74, the median forecast implies a 302.3% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Li Watsek at Cantor Fitzgerald, suggesting a 244.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SLS Analyst Ratings
3
Buy
0
Hold
0
Sell
SLS Price Target Range
Low
$6.00
Average
$7.00
High
$7.50
Current: $1.74
Latest SLS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SLS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 16, 2025 | Maxim Group | Jason McCarthy | Buy | Maintains | $7.00 |
| Nov 22, 2023 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $3.00 |
| Sep 7, 2023 | Cantor Fitzgerald | Li Watsek | Overweight | Reiterates | $3.00 |
| Nov 15, 2022 | Alliance Global Partners | James Molloy | Buy | Maintains | $8.00 |
| Jun 28, 2022 | Cantor Fitzgerald | Li Watsek | Overweight | Maintains | $6.00 |
| Jul 21, 2021 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Nov 18, 2019 | Alliance Global Partners | Buy | Initiates | $N/A | |
| Nov 18, 2019 | H.C. Wainwright | Buy | Initiates | $N/A | |
| Nov 18, 2019 | Oppenheimer | Outperform | Initiates | $N/A | |
| Nov 18, 2019 | Maxim Group | Buy | Upgrade | $N/A | |
| Nov 15, 2019 | Maxim Group | Buy | Upgrade | $N/A | |
| Apr 8, 2019 | Alliance Global Partners | Buy | Initiates | $N/A | |
| Nov 1, 2018 | Oppenheimer | Outperform | Initiates | $N/A | |
| Jul 20, 2018 | Maxim Group | Jason McCarthy | Buy | Maintains | $5.00 |
| Apr 2, 2018 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Apr 2, 2018 | H.C. Wainwright | Buy | Initiates | $N/A | |
| Mar 19, 2018 | Maxim Group | Buy | Upgrade | $N/A |
Sellas Life Sciences Group Inc. (SLS) Competitors
The following stocks are similar to SELLAS based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sellas Life Sciences Group Inc. (SLS) Financial Data
Sellas Life Sciences Group Inc. has a market capitalization of $256.55M with a P/E ratio of -3.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -84.3%.
Valuation Metrics
Market Cap
$256.55M
Enterprise Value
$204.13M
P/E Ratio
-3.5x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+17.9%
Current Ratio
8.3x
Debt/Equity
1.3x
ROE
-84.3%
ROA
-44.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sellas Life Sciences Group Inc. (SLS) Business Model
About Sellas Life Sciences Group Inc.
What They Do
Develops novel cancer immunotherapies.
Business Model
The company focuses on developing and commercializing proprietary cancer immunotherapies that enhance the immune response to various cancers. Sellas generates revenue through the advancement of its innovative treatments, partnerships with research institutions, and eventual commercialization of successful therapies.
Additional Information
Sellas Life Sciences targets hard-to-treat cancers such as acute myeloid leukemia and ovarian cancer, positioning itself in a high-impact sector of biopharmaceuticals. Its commitment to precision medicine and collaboration with cutting-edge technology enhances its potential to meet significant unmet medical needs in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
15
CEO
Dr. Angelos M. Stergiou M.D., ScD h.c.
Country
United States
IPO Year
2008
Website
www.sellaslifesciences.comSellas Life Sciences Group Inc. (SLS) Latest News & Analysis
Latest News
Quick Summary
SELLAS Life Sciences Group (SLS) held a conference to discuss advancements in AML treatments, highlighting its GPS and SLS009 programs, with key executives participating.
Why It Matters
SELLAS Life Sciences' focus on innovative AML treatments may signal potential growth and market interest, impacting share value and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
SELLAS Life Sciences Group has exercised existing warrants to purchase 22.36 million shares, raising approximately $31 million.
Why It Matters
SELLAS Life Sciences' warrant exercise indicates strong investor confidence, providing $31 million for further cancer therapy development, potentially enhancing the company's market position and share value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BlackRock has acquired a 5.4% stake in Sellas Life Sciences Group (NASDAQ: SLS), a biopharmaceutical company.
Why It Matters
BlackRock's 5.4% stake in Sellas Life Sciences signals confidence in the company's potential, which could attract more investment and drive stock performance.
Source: Finbold
Market Sentiment:
Positive
Quick Summary
SELLAS Life Sciences is advancing its WT1 immunotherapy, GPS, in Phase 3 for AML, with REGAL final analysis expected by end of 2025. SLS009, a CDK9 inhibitor, may enhance its AML applications.
Why It Matters
SELLAS Life Sciences' developments in AML therapies, particularly the promising SLS009 candidate and GPS's potential survival benefits, could enhance investor confidence and stock value.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
SELLAS Life Sciences' Phase 3 REGAL trial for galinpepimut-S in AML received a positive recommendation from the IDMC to continue without modifications, with final analysis expected by year-end after 80 events.
Why It Matters
Positive IDMC recommendation to continue the Phase 3 REGAL trial for GPS in AML suggests potential for successful drug approval, impacting SELLAS Life Sciences' stock performance and future revenue prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)
4 months ago
Quick Summary
SELLAS Life Sciences Group (SLS) has been upgraded to Zacks Rank #2 (Buy), indicating improved earnings prospects, which may positively impact the stock price.
Why It Matters
The Zacks Rank #2 upgrade signals positive earnings outlook for SELLAS Life Sciences, likely boosting investor confidence and driving the stock price upward.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About SLS Stock
What is Sellas Life Sciences Group Inc.'s (SLS) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Sellas Life Sciences Group Inc. (SLS) has a median price target of $7.00. The highest price target is $7.50 and the lowest is $6.00.
Is SLS stock a good investment in 2026?
According to current analyst ratings, SLS has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.74. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SLS stock?
Wall Street analysts predict SLS stock could reach $7.00 in the next 12 months. This represents a 302.3% increase from the current price of $1.74. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sellas Life Sciences Group Inc.'s business model?
The company focuses on developing and commercializing proprietary cancer immunotherapies that enhance the immune response to various cancers. Sellas generates revenue through the advancement of its innovative treatments, partnerships with research institutions, and eventual commercialization of successful therapies.
What is the highest forecasted price for SLS Sellas Life Sciences Group Inc.?
The highest price target for SLS is $7.50 from at , which represents a 331.0% increase from the current price of $1.74.
What is the lowest forecasted price for SLS Sellas Life Sciences Group Inc.?
The lowest price target for SLS is $6.00 from Li Watsek at Cantor Fitzgerald, which represents a 244.8% increase from the current price of $1.74.
What is the overall SLS consensus from analysts for Sellas Life Sciences Group Inc.?
The overall analyst consensus for SLS is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are SLS stock price projections?
Stock price projections, including those for Sellas Life Sciences Group Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 11:52 AM UTC